UNSPSC 51282932: Norfloxacin

This classification denotes a quinolone antibiotic with the molecular formula C16H18FN3O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier N0F8P22L1P, chemically known as 1,4-dihydro-1-ethyl-6-fluoro-4-oxo-7-(1-piperazinyl)-3-quinolinecarboxylic acid but generally known as norfloxacin, which bears US NIH Compound Identifier 4539. European Medicines Agency schedules Norfloxacin in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09365MIG. The term NORFLOXACIN is an International Non-Proprietary Name.

UNSPSC 51282932 Norfloxacin is a Commodity code that nominally names a single antibiotic product, but recent state and local solicitation activity shows little alignment with this specific pharmaceutical. The recent opportunities tagged under this code instead cover broader medical and pharmaceutical procurement categories: emergency-response medical supplies for fire departments, naloxone and drug-deactivation systems for public health, generic multi-source pharmaceuticals through cooperative purchasing, and direct-to-manufacturer prescription programs. State and local issuing bodies soliciting under or near this code include county health departments, city fire departments, state health agencies, and multi-state cooperative purchasing alliances. The divergence between the code's nominal scope (a single antibiotic) and the actual work being bought suggests either broad tagging practices in some procurement systems or limited recent activity specific to norfloxacin itself.

Geographic activity is concentrated in Florida, Texas, and Minnesota, with multistate scope through cooperative purchasing vehicles. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued an RFP (S1070000015802) posted January 20, 2026, with a response deadline of March 26, 2026, for generic multi-source pharmaceuticals and OTC products distributed across state and local facilities in Minnesota and Oregon, requiring manufacturers to supply through three authorized wholesalers and demonstrating compliance with cGMP and the Drug Supply Chain Security Act. The City of Tampa released an IFB (26P00145) posted March 25, 2026, with a response deadline of March 13, 2026, for 169 line items of medical and first aid supplies for the Tampa Fire Department Rescue Division, estimated at $700,000.00 and designated as a sheltered market opportunity exclusively for certified Small Local Business Enterprises with a 5 percent bid discount. Seminole County, Florida issued an IFB (IFB60459723LAS) posted June 30, 2026, with a response deadline of July 26, 2023, for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually through quarterly deliveries. The Texas Health and Human Services Commission posted an RFI (HHS0017013) on April 3, 2026, seeking vendor capabilities for a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program to inform future formal solicitation strategy.